The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
April 25, 2019
-
BUSINESS Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
-
BUSINESS In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
-
REGULATORY MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
-
INTERVIEW Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
-
BUSINESS MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
-
REGULATORY CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
-
BUSINESS Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
-
BUSINESS Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
-
BUSINESS With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
-
BUSINESS Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
-
BUSINESS AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
-
BUSINESS Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
-
BUSINESS Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
April 12, 2019
-
BUSINESS Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
-
BUSINESS Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
-
ORGANIZATION Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
-
REGULATORY Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
-
BUSINESS Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
-
BUSINESS Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…